- Email: [email protected]
5594033 Secoaporphine compound on arrhythmia
780
PATENT ABSTRACTS
The invention relates to a method of skin treatment comprising the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising an excipient and from about 1% to 30% lithium ion, said amount being sufficient to reduce sebum production by said skin. The invention also relates to a method of skin treatment, which comprises the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising a topically acceptable excipient and an effective amount of a lithium salt.
Novel secoaporphine compounds having the formula I (*See Patent for Chemical Structure*) wherein a) RI, R2 and R3, R4 are each methyl group; or b) R1, R2, and R4 are each methyl group; R3 is benzyl, ethyl or ailyl;or c) R1, R2, and R3 are each hydrogen, R4 is methyl; or d) R1 and R2 are each hydrogen, R3 is benzyl, R4 is methyl; or e) R1 and R2 are each hydrogen, R3 is cyano, R4 is methyl group, and a salt thereof with a pharmaceutically acceptable acid. The novel compounds are useful in the treatment of arrhythmia.
5594032
5594034
AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH INOS, INDUCERS OF INOS OR INOS CDNA
WITH 8-SUBSTITUTED-2-AMINO-
1,2,3,
4-TETRAHYDRONAPTHALENE
Gonzalez-Cadavid Nestor F; Rajfer Jacob Pasadena, CA, UNITED STATES Treatment of erectile dysfunction comprising administering to a patient, inducible Nitric Oxide Synthase (iNOS) agents, including penile iNOS, inducers of penile iNOS, iNOS cDNA, or penile smooth muscle cells transformed with iNOS cDNA. Typical in vivo treatment involves delivery of these agents to the penile tissue of a patient by constant or intermittent implanted or external infusion pump, by implantation of time-release microcapsules or introduction of the genetically-engineered cells as by injection. Also disclosed are methods of treatment involving in vitro induction of iNOS in cultured smooth muscle cells and thereafter delivery of purified or recombinant iNOS enzyme, production of iNOS cDNA and genetic transformation with iNOS cDNA, followed by delivery thereof to the penis of a patient.
5594033 SECOAPORPHINE
METHOD OF INHIBITING GASTRIC ACID SECRETION
COMPOUND
ON ARRHYTHMIA Su Ming-Jai; Teng Che-Ming; Lee Shoei-Shen Taipei, CHINA (TAIWAN) Assigned to National Science Council
Gidda Jaswant S; Schaus John Carmel, IN, UNITED STATES Assigned to Eli Lilly and Company The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.
5594091 MATRIX FOR SUSTAINED-RELEASE PREPARATION Igari Yasutaka; Saikawa Akira; Okamoto Kayoko; Kamei Shigem; 0 k a Masahisa; Sano Atsunori Hyogo, JAPAN Assigned to Takeda Chemical Industries Ltd The present invention relates to a matrix for sustained-release preparation comprising an ester formed at a terminal carboxyl group of a straight-chain polyester which essentially consists of an alpha-hydroxymonocarboxylic acid. The matrix is stable to light, heat, moisture, coloring etc., and is of low toxicity. The sustained-release preparation produced by using the ester of the present invention offers stable drug release over an extended period of time, ensuring sustained
PATENT ABSTRACTS
The invention relates to a method of skin treatment comprising the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising an excipient and from about 1% to 30% lithium ion, said amount being sufficient to reduce sebum production by said skin. The invention also relates to a method of skin treatment, which comprises the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising a topically acceptable excipient and an effective amount of a lithium salt.
Novel secoaporphine compounds having the formula I (*See Patent for Chemical Structure*) wherein a) RI, R2 and R3, R4 are each methyl group; or b) R1, R2, and R4 are each methyl group; R3 is benzyl, ethyl or ailyl;or c) R1, R2, and R3 are each hydrogen, R4 is methyl; or d) R1 and R2 are each hydrogen, R3 is benzyl, R4 is methyl; or e) R1 and R2 are each hydrogen, R3 is cyano, R4 is methyl group, and a salt thereof with a pharmaceutically acceptable acid. The novel compounds are useful in the treatment of arrhythmia.
5594032
5594034
AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH INOS, INDUCERS OF INOS OR INOS CDNA
WITH 8-SUBSTITUTED-2-AMINO-
1,2,3,
4-TETRAHYDRONAPTHALENE
Gonzalez-Cadavid Nestor F; Rajfer Jacob Pasadena, CA, UNITED STATES Treatment of erectile dysfunction comprising administering to a patient, inducible Nitric Oxide Synthase (iNOS) agents, including penile iNOS, inducers of penile iNOS, iNOS cDNA, or penile smooth muscle cells transformed with iNOS cDNA. Typical in vivo treatment involves delivery of these agents to the penile tissue of a patient by constant or intermittent implanted or external infusion pump, by implantation of time-release microcapsules or introduction of the genetically-engineered cells as by injection. Also disclosed are methods of treatment involving in vitro induction of iNOS in cultured smooth muscle cells and thereafter delivery of purified or recombinant iNOS enzyme, production of iNOS cDNA and genetic transformation with iNOS cDNA, followed by delivery thereof to the penis of a patient.
5594033 SECOAPORPHINE
METHOD OF INHIBITING GASTRIC ACID SECRETION
COMPOUND
ON ARRHYTHMIA Su Ming-Jai; Teng Che-Ming; Lee Shoei-Shen Taipei, CHINA (TAIWAN) Assigned to National Science Council
Gidda Jaswant S; Schaus John Carmel, IN, UNITED STATES Assigned to Eli Lilly and Company The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.
5594091 MATRIX FOR SUSTAINED-RELEASE PREPARATION Igari Yasutaka; Saikawa Akira; Okamoto Kayoko; Kamei Shigem; 0 k a Masahisa; Sano Atsunori Hyogo, JAPAN Assigned to Takeda Chemical Industries Ltd The present invention relates to a matrix for sustained-release preparation comprising an ester formed at a terminal carboxyl group of a straight-chain polyester which essentially consists of an alpha-hydroxymonocarboxylic acid. The matrix is stable to light, heat, moisture, coloring etc., and is of low toxicity. The sustained-release preparation produced by using the ester of the present invention offers stable drug release over an extended period of time, ensuring sustained